Bhageria Industries reported a standalone net profit of ₹359.44 crore for the quarter ended June 30, 2026, marking a 155% increase from ₹119.90 crore in the corresponding period of the previous year. Revenue from operations surged 80% to ₹2,840.19 crore, driven by robust performance in the Chemicals segment. EBITDA for the quarter rose to 400M rupees from 183M rupees in the year-ago period, with the EBITDA margin expanding to 14.10% from 11.55%. The company's Board approved the unaudited standalone and consolidated financial results for Q1FY27 at a meeting held on July 22, 2026.

Financial Performance

The total income for the quarter stood at ₹3,007.76 crore, up from ₹1,647.51 crore in Q1FY26. Total expenses increased to ₹2,523.81 crore from ₹1,482.21 crore. The profit before tax rose to ₹483.96 crore from ₹165.30 crore in the prior year quarter. Basic earnings per share (EPS) for the quarter were recorded at ₹8.24, compared to ₹2.75 in the same period last year. The key standalone financial metrics are summarised below:

Segment Results

The Chemicals segment remained the primary revenue driver, contributing ₹2,741.75 crore to the segment revenue. The Solar Power segment reported revenue of ₹82.97 crore, while the Pharma segment recorded ₹7.03 crore. The company identified Chemicals, Solar Power, Pharma, and Others as its reportable segments under Ind AS 108.

Consolidated Results

On a consolidated basis, the company reported a net profit of ₹339.11 crore for Q1FY27, compared to ₹108.83 crore in the year-ago period. Consolidated revenue from operations stood at ₹2,864.18 crore. Total comprehensive income for the period attributable to the owners of the company was ₹342.42 crore. The consolidated results include the financial performance of six subsidiaries, including Bhageria & Jajodia Pharmaceuticals Private Limited and Hikaru Solar Power Private Limited.

Auditor Review

The statutory auditors, Sarda & Pareek LLP, conducted a limited review of the standalone and consolidated financial results. In their report, the auditors stated that the results give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards. The auditors also noted that figures for the quarter ended March 31, 2026, are balancing figures between audited annual figures and published year-to-date figures up to the third quarter.

Bhageria Industries Limited has released its Integrated Annual Report for FY2025-26, reporting robust growth across its core business segments. On a standalone basis, the company achieved total income of ₹880.56 crore for the year ended March 31, 2026, compared to ₹604.07 crore in FY2024-25 — a growth of 45.77%. Net profit after tax rose to ₹50.30 crore from ₹42.27 crore in the previous year, while earnings per share improved to ₹11.52 from ₹9.68. The Board of Directors has recommended a final dividend of ₹2.50 per equity share of face value ₹5 each, representing a 50% dividend on the paid-up equity share capital and a payout of 21.69% of profits, subject to shareholder approval at the 37th Annual General Meeting scheduled for August 1, 2026.

Financial Performance Overview

The company's financial results for FY2025-26 reflect significant top-line expansion alongside steady profitability. The following table summarises the key standalone and consolidated financial metrics:

On a consolidated basis, total income grew to ₹880.79 crore from ₹601.59 crore, registering a growth of 46.41%. Consolidated EBITDA stood at ₹98.00 crore compared to ₹88.40 crore in FY2024-25, while consolidated PAT stood at ₹44.49 crore versus ₹38.69 crore in the prior year. The consolidated net worth as at March 31, 2026 stood at ₹456.53 crore.

Segment-wise Performance

The company operates across three primary business segments — Chemicals, Solar Power, and Pharmaceuticals. The Chemical segment was the dominant contributor to revenues in FY2025-26, as detailed below:

On a consolidated basis, the Chemical segment turnover was ₹829.56 crore (FY25: ₹504.31 crore) with EBIT of ₹69.26 crore (FY25: ₹56.46 crore). Consolidated Solar Power turnover stood at ₹27.13 crore (FY25: ₹27.83 crore) with EBIT of ₹11.39 crore, while the Pharma segment reported consolidated turnover of ₹6.45 crore (FY25: ₹5.57 crore) with an EBIT of (₹7.54) crore. Plant utilisation in the Chemical segment held at 95–97% through much of the year, supported by sustained export demand from customers in Southeast Asia and Europe. The company also commenced production of Plasticizers — a new product — at its Tarapur facility during the year.

Solar Energy Expansion

On the renewable energy front, the company's subsidiary Rahuri Cleantech Private Limited successfully commissioned a 14 MW solar power plant during FY2025-26. An additional 7 MW was commissioned in May 2026, taking total installed capacity to 21 MW. This plant forms part of a larger 32 MW capacity build-out under Maharashtra's MSKVY 2.0 scheme. Separately, the company undertook development of a 2.25 MW DC Solar Power Plant at Tapi, Songadh, Gujarat, for self-captive consumption, which is currently under implementation.

Key Financial Ratios

The following standalone key financial ratios reflect the company's operational and financial position for FY2025-26:

The improvement in inventory and receivables turnover ratios reflects enhanced working capital management. The decline in the Debt-Equity Ratio was primarily on account of reduction in borrowings and improvement in net worth. The decline in Operating Profit Margin was attributable to changes in product mix, competitive market conditions, and higher input costs.

Corporate Governance and Board Matters

The Board of Directors comprises seven directors as on March 31, 2026 — three Executive Directors and four Independent Directors, including one Woman Director. The Board met four times during FY2025-26. At the forthcoming 37th AGM, members will consider the re-appointment of Mr. Suresh Bhageria as Executive Director & Chairman (WTD), Mr. Vinod Bhageria as Managing Director, and Mr. Vikas Bhageria as Jt. Managing Director, each for a period of three years commencing April 1, 2027 up to March 31, 2030. The remuneration of Cost Auditors M/s K V M & Co. at ₹2,00,000/- plus GST for FY2026-27 is also proposed for ratification.

The following table summarises the key AGM agenda items:

During the year, the company completed the voluntary liquidation of its wholly owned subsidiary Bhageria Industries Holding Company WLL, incorporated in the Kingdom of Bahrain, with effect from November 20, 2025. As on March 31, 2026, the company has five subsidiary companies: Bhageria & Jajodia Pharmaceuticals Private Limited, Rahuri Cleantech Private Limited, Salasar Renewables Private Limited, Hikaru Solar Power Private Limited, and New Ahilyanagar Solar Private Limited.

Foreign Exchange and CSR

Foreign exchange earned during FY2025-26 stood at ₹30,371.92 lakhs, compared to ₹9,109.94 lakhs in FY2024-25. Foreign exchange outgo was ₹9,294.18 lakhs versus ₹9,295.99 lakhs in the prior year. On CSR, the company incurred expenditure of ₹33.99 lakhs during FY2025-26 against a statutory CSR obligation of ₹70.51 lakhs, utilising an eligible set-off balance of ₹280.51 lakhs arising from excess CSR expenditure incurred during FY2023-24 and FY2024-25. The company had 457 permanent employees on its rolls as on March 31, 2026.